EACS Guidelines
Advanced Search…
  • Log in

Navigation

  • Home
  • Contents
    • Summary of Changes from v.10.1 to v.11.0
    • Abbreviations
    • Version Information
  • Assessment
  • ART
    • Readiness to Start/Maintain ART
    • Initial Regimens: ART-naïve Adult
    • Primary HIV Infection (PHI)
    • Switch Strategies
    • Virological Failure
    • Initiation of ART: No Prior ART Exposure
    • Pregnancy and HIV
    • ART: TB/HIV Co-infection
    • Post-exposure Prophylaxis (PEP)
    • Pre-exposure Prophylaxis (PrEP)
    • ARV Adverse Effects & Drug Classes
  • DDIs & Prescribing Issues
    • DDIs, Prescribing, Overview
    • Drug-drug interactions
      • Analgesics & ARVs
      • Anti-coagulants/Antiplatelet Agents & ARVs
      • Anti-depressants & ARVs
      • Anti-hypertensives & ARVs
      • Anti-malarial Drugs & ARVs
      • Anti-tuberculosis drugs & ARVs
      • Anxiolytics & ARVs
      • ARVs & non-ARVs
      • Bronchodilators & ARVs
      • Contraceptives & ARVs
      • Corticosteroids & ARVs
      • COVID-19 Therapies & ARVs
      • Hormone Replacement Therapy (HRT) & ARVs
      • Immunosuppressants & ARVs
      • Pulmonary Anti-hypertensives & ARVs
      • Viral Hepatitis Drugs & ARVs
    • Other prescribing issues
      • ARVs: Swallowing Difficulties
      • ARV Dosing: Hepatic Impairment
      • ARV Dosing: Renal Impairment
      • Non-ARV Drug Dosing: Renal Insufficiency
      • Prescribing in Older PLWH
      • Drug Classes To Avoid: Older PLWH
      • Hormone Therapy: Gender Transitioning
  • Co-morbidities
    • Co-morbidities, Overview
    • Opioid Addiction
    • Cancer
      • Cancer Screening
      • Cancer: Treatment Monitoring
    • Lifestyle Interventions
    • Cardiovascular Disease
      • Prevention of Cardiovascular Disease (CVD)
      • Hypertension: Diagnosis, Grading & Management
      • Hypertension: Drug Sequencing Management
      • DDIs: Anti-hypertensives & ARVs
    • Type 2 Diabetes
    • Dyslipidemia
      • Dyslipidaemia
      • Treatment Goals for LDL-c for Very High and High CVD Risk Persons
    • Bone Disease
      • Bone Disease
      • Vitamin D Deficiency
      • Fracture Reduction
    • Kidney disease
      • Kidney Disease: Definition, Diagnosis and Management
      • ARV-associated Nephrotoxicity
      • Proximal Renal Tubulopathy (PRT)
      • ARV dosing: renal impairment
    • Liver Disease
      • Increased ALT/AST: Work-up & Management
      • Liver Cirrhosis: Classification, Surveillance
      • Liver Cirrhosis: Management
      • Non-Alcoholic Fatty Liver Disease (NAFLD)
      • Hepatorenal Syndrome /Acute Kidney Injury (HRS-AKI)
      • ARV Dosing: Hepatic Impairment
    • Lipodystrophy and Obesity:
    • Hyperlactataemia and Lactic Acidosis
    • Travel
      • Travel
      • DDI: Antimalarial Drugs & ARVs
    • Vaccination
    • Sexual, Reproductive Health
      • Sexual and Reproductive Health of PLWH
      • Sexual Dysfunction
      • Treatment of Sexual Dysfunction in PLWH
    • Mental Health in PLWH: Depression & Anxiety Disorders
      • Depression: Screening, Diagnosis, Management
      • Antidepressants
      • DDI: Antidepressants and ARVs
      • Anxiety Disorders: Screening and Diagnosis
      • Anxiety Disorders: Management
      • Classification, Doses and Adverse Effects of Anxiolytics
      • DDI: Anxiolytics & ARVs
    • Cognitive Impairment
    • Chronic Lung Disease
      • Chronic Lung Disease
      • DDI: Bronchodilators & ARVs
      • DDI: Pulmonary Antihypertensives & ARVs
    • Managing Older PLWH
    • Frailty
    • Falls
    • Solid Organ Transplant (SOT)
      • Solid Organ Transplantation (SOT)
      • DDI: Immunosuppressants & ARVs
  • HIV/Hep Co-infection
    • Clinical Management and Treatment of Viral Hepatitis Co-infections in PLWH
    • Treatment and Monitoring of Persons with HBV/HIV Co-infection
    • HCV/HIV Co-infection
      • Treatment and Monitoring of Persons with HCV/HIV Co-infection
      • HCV Treatment Options
      • DDIs: HCV DAAs & ARVs
      • Recently Acquired HCV Infection
    • Tests: Fibrosis / Cirrhosis
    • Hepatitis D and E
  • Opportunistic Infections, COVID-19
    • Opportunistic Infections and COVID-19, Overview
    • Immune Reconstitution Inflammatory Syndrome (IRIS)
    • Primary Prophylaxis of OIs
    • Bacillary Angiomatosis
    • Candidiasis
    • Cryptococcosis
    • Cryptosporidiosis
    • Cystoisosporiasis
    • Cytomegalovirus (CMV)
    • Herpes Simplex Virus (HSV)
    • Histoplasmosis
    • Leishmaniasis
    • Non-Tuberculous Mycobacteria (NTM)
    • Pneumocystis jirovecii Pneumonia (PcP)
    • Progressive Multifocal Leukoencephalopathy (PML)
    • Talaromycosis
    • Toxoplasma gondii Encephalitis
    • Tuberculosis
    • Varicella Zoster Virus (VZV)
    • Management of COVID-19 in PLWH
  • Paediatric HIV Treatment
    • ART: Initiation and Initial Regimen
    • ART: Preferred & Alternative First Line Options, Formulations, Dosing
    • Switch Strategies, Special Populations
    • Adherence, Virological Failure, Second Line ART
  • Video Links
  • References
    • References, Overview
    • Assessment of PLWH at Initial & Subsequent Visits, References
    • ARV Treatment of PLWH, References
    • DDIs & Other Prescribing Issues, References
    • Co-morbidities Prevention & Management, References
    • Chronic Viral Hepatitis Co-infections, References
    • Opportunistic Infections and COVID-19, References
    • Paediatric HIV Treatment References
You are here:
  1. Home
  2. Co-morbidities
  3. Dyslipidemia
Dyslipidemia https://eacs.sanfordguide.com/prevention-non-infectious-co-morbidities/dyslipidemia https://eacs.sanfordguide.com/@@site-logo/eacs-logo.png

Dyslipidemia

Dyslipidaemia
Treatment Goals for LDL-c for Very High and High CVD Risk Persons
© EACS - All Rights Reserved | Privacy Policy